KB
GSK icon

Kahn Brothers’s GSK GSK Stock Holding History

Kahn Brothers’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.31M Sell
158,438
-2,544
-2% -$135K 1.31% 17
2026
Q1 		$8.88M Sell
160,982
-17,714
-10% -$960K 1.58% 17
2025
Q4 		$8.76M Sell
178,696
-82,141
-31% -$3.83M 1.55% 15
2025
Q3 		$11.3M Sell
260,837
-399,035
-60% -$15.6M 2.12% 14
2025
Q2 		$25.3M Sell
659,872
-162,355
-20% -$6.2M 5.09% 10
2025
Q1 		$31.9M Sell
822,227
-62,481
-7% -$2.29M 6.44% 9
2024
Q4 		$29.9M Sell
884,708
-174,124
-16% -$6.27M 6.5% 7
2024
Q3 		$43.3M Sell
1,058,832
-182,429
-15% -$7.46M 7.46% 6
2024
Q2 		$47.8M Sell
1,241,261
-12,383
-1% -$521K 8.03% 4
2024
Q1 		$53.7M Sell
1,253,644
-5,838
-0.5% -$241K 7.97% 5
2023
Q4 		$46.7M Sell
1,259,482
-22,807
-2% -$819K 7.35% 6
2023
Q3 		$46.5M Buy
1,282,289
+18,831
+1% +$668K 7.25% 8
2023
Q2 		$45M Sell
1,263,458
-14,018
-1% -$503K 6.6% 8
2023
Q1 		$45.5M Buy
1,277,476
+50,570
+4% +$1.77M 6.54% 8
2022
Q4 		$43.1M Sell
1,226,906
-78,033
-6% -$2.6M 5.68% 10
2022
Q3 		$38.4M Buy
1,304,939
+160,011
+14% +$6.06M 5.98% 10
2022
Q2 		$62.3M Buy
1,144,928
+3,597
+0.3% +$199K 8.39% 6
2022
Q1 		$62.1M Sell
1,141,331
-9,524
-0.8% -$517K 7.89% 6
2021
Q4 		$63.4M Buy
1,150,855
+68,169
+6% +$3.55M 8.71% 3
2021
Q3 		$51.7M Buy
1,082,686
+44,999
+4% +$2.26M 7.28% 8
2021
Q2 		$51.7M Buy
1,037,687
+25,071
+2% +$1.2M 7.4% 9
2021
Q1 		$45.2M Sell
1,012,616
-12,923
-1% -$587K 6.99% 8
2020
Q4 		$47.2M Sell
1,025,539
-99,812
-9% -$4.58M 8.23% 5
2020
Q3 		$52.9M Sell
1,125,351
-88,983
-7% -$4.46M 10.04% 3
2020
Q2 		$62.2M Sell
1,214,334
-20,560
-2% -$1.05M 10.51% 2
2020
Q1 		$58.5M Sell
1,234,894
-35,208
-3% -$1.88M 10.7% 2
2019
Q4 		$74.6M Sell
1,270,102
-26,377
-2% -$1.47M 9.05% 4
2019
Q3 		$69.2M Buy
1,296,479
+12,468
+1% +$641K 8.67% 5
2019
Q2 		$64.2M Buy
1,284,011
+262,771
+26% +$13.2M 8.03% 5
2019
Q1 		$53.3M Buy
1,021,240
+12,488
+1% +$624K 8.34% 5
2018
Q4 		$48.2M Buy
1,008,752
+15,539
+2% +$765K 8.69% 5
2018
Q3 		$49.9M Buy
993,213
+3,939
+0.4% +$200K 7.66% 6
2018
Q2 		$49.8M Buy
989,274
+4,760
+0.5% +$240K 7.93% 4
2018
Q1 		$48.1M Buy
984,514
+73,184
+8% +$3.41M 7.66% 6
2017
Q4 		$40.4M Buy
911,330
+94,422
+12% +$4.36M 6.35% 6
2017
Q3 		$41.5M Sell
816,908
-27,160
-3% -$1.38M 6.33% 6
2017
Q2 		$45.5M Buy
844,068
+3,272
+0.4% +$174K 6.94% 5
2017
Q1 		$44.3M Buy
840,796
+174,144
+26% +$8.83M 7.62% 5
2016
Q4 		$32.1M Buy
+666,652
New +$32.9M 5.42% 9

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kahn Brothers's GSK Position: Q2 2026 in Review

Kahn Brothers reduced its GSK (GSK) stake by 1.6% in Q2 2026, selling an estimated $135K and leaving 158,438 shares worth $8.31M. The position accounts for 1.31% of the portfolio, ranked #17.

Kahn Brothers first reported a position in GSK in Q4 2016 and has held it in 39 quarters since. The position peaked at $74.6M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Kahn Brothers held 158,438 shares of GSK worth $8.31M as of Q2 2026.
  • Kahn Brothers sold 2,544 GSK shares in Q2 2026, an estimated $135K.
  • GSK made up 1.31% of Kahn Brothers's portfolio in Q2 2026, its #17 holding.
  • Kahn Brothers first reported a position in GSK in Q4 2016 and has held it in 39 quarters since.
  • Kahn Brothers's GSK position peaked at $74.6M in Q4 2019.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kahn Brothers Group's 13F filing for Q2 2026, filed 14 Aug 2026.